NCT03739905 is a NA clinical trial of Blood Brain Barrier (BBB) Disruption in Alzheimer Disease, sponsored by InSightec.

Who is sponsoring NCT03739905?

NCT03739905 is sponsored by InSightec.

What drugs are being tested in NCT03739905?

Interventions in NCT03739905: Blood Brain Barrier (BBB) Disruption.

What condition does NCT03739905 study?

NCT03739905 studies Alzheimer Disease.

Is NCT03739905 still recruiting?

NCT03739905 is currently completed. Last updated 21 January 2026.

Last reviewed 2026-01-21 · How we verify

NCT03739905

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ExAblate Blood-Brain Barrier Opening for Treatment of Alzheimer's Disease

Completed NA Last updated 21 January 2026

What this trial tests

NA trial testing Blood Brain Barrier (BBB) Disruption in Alzheimer Disease in 35 participants. Completed in 9 April 2025.

Timeline

6 December 2018

Primary endpoint
9 April 2025

9 April 2025

Quick facts

Lead sponsor	InSightec
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	6 December 2018
Primary completion	9 April 2025
Estimated completion	9 April 2025
Sites	1 location across Canada

Drugs / interventions tested

Blood Brain Barrier (BBB) Disruption

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

InSightec — full company profile →

Who can join

Adults 50 to 85, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of the ExAblate® Model 4000 Type 2.0 system as a tool to open the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Alzheimer's disease drug development pipeline: 2019.
Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2019 · cited 485× · PMID 31334330 · DOI 10.1016/j.trci.2019.05.008
Treatment of Alzheimer's Disease and Blood-Brain Barrier Drug Delivery.
Pardridge WM. · · 2020 · cited 131× · PMID 33207605 · DOI 10.3390/ph13110394
Current Strategies to Enhance Delivery of Drugs across the Blood-Brain Barrier.
Teleanu RI, Preda MD, Niculescu AG, Vladâcenco O, et al · · 2022 · cited 122× · PMID 35631573 · DOI 10.3390/pharmaceutics14050987
MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors.
Meng Y, Pople CB, Suppiah S, Llinas M, et al · · 2021 · cited 116× · PMID 33693781 · DOI 10.1093/neuonc/noab057
Theranostic Strategy of Focused Ultrasound Induced Blood-Brain Barrier Opening for CNS Disease Treatment.
Chen KT, Wei KC, Liu HL. · · 2019 · cited 108× · PMID 30792657 · DOI 10.3389/fphar.2019.00086
Applications of focused ultrasound-mediated blood-brain barrier opening.
Gorick CM, Breza VR, Nowak KM, Cheng VWT, et al · · 2022 · cited 95× · PMID 36272635 · DOI 10.1016/j.addr.2022.114583
Secondary effects on brain physiology caused by focused ultrasound-mediated disruption of the blood-brain barrier.
Todd N, Angolano C, Ferran C, Devor A, et al · · 2020 · cited 94× · PMID 32470359 · DOI 10.1016/j.jconrel.2020.05.040
Therapeutic Agent Delivery Across the Blood-Brain Barrier Using Focused Ultrasound.
McMahon D, O'Reilly MA, Hynynen K. · · 2021 · cited 67× · PMID 33752471 · DOI 10.1146/annurev-bioeng-062117-121238

Verify or expand the search:

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Other InSightec trials

Trials by the same sponsor.

NCT04667715 — Safety and Effectiveness of Blood-Brain Barrier Disruption (BBBD) in Subjects With Suspected Infiltrating Glioma · NA · withdrawn
NCT05539196 — A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advance · recruiting
NCT05089786 — Echo-Focusing in Patients With Treatment-Resistant Neurologic and Psychiatric Indications (EF001) · NA · unknown
NCT05565443 — MR-guided Focused Ultrasound Plus GCase · NA · recruiting
NCT05317858 — Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03739905 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by InSightec
Last refreshed: 21 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03739905.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing